Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
(ANTX) stock logo
ANTX
(ANTX)
$1.14
-7.0%
$0.00
$0.87
$2.74
$33.76M0.15360,333 shs83,337 shs
OS Therapies Inc stock logo
OSTX
OS Therapies
$2.48
+3.3%
$1.83
$1.12
$7.00
$79.09MN/A737,634 shs1.08 million shs
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
$4.95
+0.2%
$4.83
$0.13
$1.04
$95.30M1.581.05 million shs6,032 shs
WHWK
Whitehawk Therapeutics
$1.74
+5.5%
$1.83
$1.39
$3.81
$82.01M0.55100,515 shs70,989 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
(ANTX) stock logo
ANTX
(ANTX)
0.00%+4.13%+4.13%-4.62%+3.18%
OS Therapies Inc stock logo
OSTX
OS Therapies
0.00%+20.39%+37.78%+47.62%-40.24%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
0.00%+0.37%+4.62%-5.56%+2,250.78%
WHWK
Whitehawk Therapeutics
0.00%+8.75%-10.77%+173,999,900.00%+173,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/AN/AN/AN/AN/A
OS Therapies Inc stock logo
OSTX
OS Therapies
2.3771 of 5 stars
3.60.00.00.02.80.80.6
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
WHWK
Whitehawk Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
(ANTX) stock logo
ANTX
(ANTX)
2.50
Moderate Buy$2.0076.21% Upside
OS Therapies Inc stock logo
OSTX
OS Therapies
3.25
Buy$18.00625.81% Upside
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
2.00
Hold$5.001.04% Upside
WHWK
Whitehawk Therapeutics
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest ANTX, VIRI, WHWK, and OSTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
8/11/2025
WHWK
Whitehawk Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell
8/7/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
7/14/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/30/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/24/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/9/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/A$4.19 per shareN/A
OS Therapies Inc stock logo
OSTX
OS Therapies
N/AN/AN/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/A$0.20 per shareN/A
WHWK
Whitehawk Therapeutics
$25.98M3.16N/AN/A$2.12 per share0.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
(ANTX) stock logo
ANTX
(ANTX)
-$64.73M-$2.04N/AN/AN/AN/A-57.62%-52.08%N/A
OS Therapies Inc stock logo
OSTX
OS Therapies
-$7.79M-$0.79N/AN/AN/AN/AN/A-569.57%N/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%N/A
WHWK
Whitehawk Therapeutics
-$63.69M-$0.06N/AN/A99.42%-75.99%-68.57%N/A

Latest ANTX, VIRI, WHWK, and OSTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
WHWK
Whitehawk Therapeutics
$0.49-$0.76-$1.25-$0.76$100.00 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/AN/A
OS Therapies Inc stock logo
OSTX
OS Therapies
N/AN/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/A
WHWK
Whitehawk Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
(ANTX) stock logo
ANTX
(ANTX)
N/A
9.75
9.75
OS Therapies Inc stock logo
OSTX
OS Therapies
N/A
0.76
0.76
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/A
7.27
7.27
WHWK
Whitehawk Therapeutics
N/A
20.41
20.41

Institutional Ownership

CompanyInstitutional Ownership
(ANTX) stock logo
ANTX
(ANTX)
90.47%
OS Therapies Inc stock logo
OSTX
OS Therapies
N/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
9.05%
WHWK
Whitehawk Therapeutics
52.08%

Insider Ownership

CompanyInsider Ownership
(ANTX) stock logo
ANTX
(ANTX)
20.79%
OS Therapies Inc stock logo
OSTX
OS Therapies
13.80%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
12.20%
WHWK
Whitehawk Therapeutics
49.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
(ANTX) stock logo
ANTX
(ANTX)
N/A29.88 million23.67 millionNot Optionable
OS Therapies Inc stock logo
OSTX
OS Therapies
N/A31.89 millionN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
519.26 million16.91 millionOptionable
WHWK
Whitehawk Therapeutics
4047.13 million23.61 millionN/A

New MarketBeat Followers Over Time

Media Sentiment Over Time

(ANTX) stock logo

(ANTX) NYSE:ANTX

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

OS Therapies stock logo

OS Therapies NYSE:OSTX

$2.48 +0.08 (+3.33%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$2.51 +0.03 (+1.17%)
As of 06:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Virios Therapeutics stock logo

Virios Therapeutics NASDAQ:VIRI

$4.95 +0.01 (+0.17%)
As of 08/22/2025

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Whitehawk Therapeutics NASDAQ:WHWK

$1.74 +0.09 (+5.45%)
As of 08/22/2025 04:00 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.